CA-CEPTON-TECHNOLOGIES
11.10.2021 15:02:06 CEST | Business Wire | Press release
Cepton Technologies, Inc., an innovative provider of smart lidar solutions , announced today its membership in the Qualcomm® Smart Cities Accelerator Program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005191/en/
The Qualcomm Smart Cities Accelerator Program brings technologies and companies together to collaborate, innovate, and accelerate the rollout of smart cities and smart connected spaces globally. Cepton believes its presence in this ecosystem aligns with Qualcomm Technologies, Inc.’s vision of bringing efficient, safe, and advanced technology to fast-growing urban environments. With its membership, Cepton aims to advance the use of lidar-based solutions with ecosystem members of the Qualcomm Smart Cities Accelerator Program across smart cities and smart connected spaces.
Through the Qualcomm® IoT Services Suite, Cepton and one of its key partners in smart spaces, The Indoor Lab, plan to collaborate with Qualcomm Technologies in offering Smart Venues as a Service , utilizing a lidar-based crowd analytics system which adheres to the privacy concerns and optimizes the utilization of spaces.
With its high-accuracy, 3D perception capabilities and 24/7 availability , lidar can enable a wide range of applications to help build safer, smarter, and better-connected environments. Thanks to their anonymized data, lidars maximize protection of people’s privacy as they collect useful information to help drive intelligent decisions in smart cities and smart spaces. Cepton has been working with global partners to enable the transformation of transportation infrastructure, public venues and large commercial facilities using smart lidar solutions. For example, Cepton’s partnership with The Indoor Lab deployed a lidar-based crowd analytics solution as a pilot project at an Orlando International Airport terminal in 2020 to offer anonymous foot fall tracking, helping maintenance crews in targeted cleaning and travelers in avoiding crowded areas.
“We are proud to join Qualcomm Technologies’ network of technology innovators through the Qualcomm Smart Cities Accelerator Program as we work to help advance the future of smart infrastructure with our lidar technologies,” said Dr. Jun Pei, CEO of Cepton. “To date, our technology has been successfully used to enable real-time traffic and pedestrian monitoring at road and rail intersections , free-flow electronic tolling systems , critical infrastructure security , and crowd analytics . By joining the Qualcomm Smart Cities Accelerator Program ecosystem, we look forward to making our technologies more accessible on a global scale.”
“Our partnership with Cepton has been invaluable to establish The Indoor Lab as a market leader for lidar-based analytics,” said Patrick Blattner, Co-Founder and Chief Product Officer of The Indoor Lab . “Last week at the 3rd Annual Qualcomm Smart Cities Accelerate Event, we were proud to showcase our solution and its wide variety of applications to the global Qualcomm Smart Cities Accelerator Program ecosystem.”
"We are pleased to welcome Cepton as a member of our cutting-edge Qualcomm Smart Cities Accelerator Program. We look forward to working together to bring cutting-edge smart lidar solutions and applications to a variety of urban environments and collaborating to offer Smart Venues as a Service through the Qualcomm® IoT Services Suite," said Sanjeet Pandit, Senior Director, Business Development, and Global Head of Smart Cities, Qualcomm Technologies, Inc.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm Smart Cities Accelerator Program is a program of Qualcomm Technologies, Inc. and/or its subsidiaries.
Qualcomm IoT Services Suite is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005191/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom